H115 saw Biotie successfully complete an equity raise through the issue of convertible notes (€33m) and a US IPO (€50m), with net proceeds of €74.3m. The funds raised enabled the start of the pivotal Phase III study, TOZ-PD, for lead product candidate tozadenant in Parkinson’s diseas (PD). Biotie continues to receive a steady stream of royalties from Selincro, a novel treatment concept for alcohol dependence, which is partnered with Lundbeck across Europe. Two other produ
01 Sep 2015
In pivotal territory
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
In pivotal territory
- Published:
01 Sep 2015 - Author:
- Pages:
H115 saw Biotie successfully complete an equity raise through the issue of convertible notes (€33m) and a US IPO (€50m), with net proceeds of €74.3m. The funds raised enabled the start of the pivotal Phase III study, TOZ-PD, for lead product candidate tozadenant in Parkinson’s diseas (PD). Biotie continues to receive a steady stream of royalties from Selincro, a novel treatment concept for alcohol dependence, which is partnered with Lundbeck across Europe. Two other produ